Ambrisentan - Wikipedia, the free encyclopedia
Ambrisentan (U.S. trade name Letairis; E.U. trade name Volibris) is a drug indicated for use in the treatment of pulmonary hypertension. It functions as an endothelin receptor ...
Endothelin receptor antagonist - Wikipedia, the free encyclopedia
A endothelin receptor antagonist (ERA) is a drug that blocks endothelin receptors. Two main kinds of ERAs exist: selective ERAs (sitaxentan, ambrisentan, atrasentan), which affect ...
GlaxoSmithKline's Volibris (ambrisentan) receives authorisation from ...
This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.
Newly Approved Drug Therapies (956) Letairis (ambrisentan), Gilead,
Organized by therapeutic area, this comprehensive listing of FDA-Approved Drugs by the Food and Drug Administration features facts on clinical trial results, side effects and other ...
Letairis Package Insert
Ambrisentan is practically insoluble in water and in aqueous solutions at low pH. Solubility increases in aqueous solutions at higher pH. In the solid state ambrisentan is very ...
CIGNA - ambrisentan
This medication can cause birth defects. Do not use if you are pregnant. Tell your doctor right away if you miss a menstrual period during treatment with ambrisentan.
PAH - AMBRISENTAN
Ambrisentan is an ETA selective receptor antagonist being developed as an oral therapy for patients with pulmonary arterial hypertension. Ambrisentan is member of a class of ...
Ambrisentan, a non-peptide endothelin receptor antagonist.
1: Cardiovasc Drug Rev. 2006 Spring;24(1):63-76. Ambrisentan, a non-peptide endothelin receptor antagonist. Vatter H, Seifert V. Department of Neurosurgery, Johann Wolfgang Goethe ...
Four Ambrisentan Studies to Be Presented at Chest 2006 -- Salt Lake ...
DENVER--(BUSINESS WIRE)--Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the ...
GlaxoSmithKline's Volibris (ambrisentan) Receives Authorisation From ...
GlaxoSmithKline (GSK) announced that the European Commission has issued marketing authorisation for Volibris® (ambrisentan) for the treatment of Pulmonary Arterial Hypertension ...
Ambrisentan
What is this medicine? AMBRISENTAN (am bri SEN tan) is used to treat pulmonary hypertension. This medicine may help make exercise and breathing easier.
